Anika Therapeutics Inc. · NASDAQ:ANIK
Anika Therapeutics — Shareholder Meeting (May 2022)
12 slides from Anika Therapeutics's shareholder meeting presentation, May 9, 2022
Slide 1: Stockholder Engagement for 2022 Annual Meeting
ANIKA. RESTORE ACTIVE LIVING. ΠANIKA THERAPEUTICS STOCKHOLDER ENGAGEMENT FOR 2022 ANNUAL MEETING MAY 2022
Slide 2: The Board asks that you vote FOR all proposals
The Board of Directors asks that you vote FOR all proposals ANIKA REQUESTS YOUR SUPPORT AT THE 2022 ANNUAL MEETING OF STOCKH OLDERS • Proposal 1 – FOR Election of Two Class II Directors • Cheryl R. Blanchard, Ph.D. and Glenn R. Larsen, Ph.D. • Proposal 2 – FOR Amendment of 2017 Omnibus Incentive Pla
Slide 3: Our Values, Vision and Mission
3 Our Values CUSTOMERS AND PATIENTS ACCOUNTABILITY INNOVATION INTEGRITY PEOPLE We engage with and invest in QUALITY We strive for the highest quality and compliance in everything we do. We live up to our promises and do the right thing, every day. We are agile and entrepreneurial in developing and d
Slide 4: Anika Snapshot
61% 33% 6% 90% 2% 8% Key Statistics Founded 1992 Headquarters Bedford, MA Total Employees ~300 Countries Served 75+ 2021 Revenue $148M 2021 Cash & Investments $94M ANIKA SNAPSHOT (NASDAQ: ANIK) 4 RESTORING ACTIVE LIVING FOR PEOPLE AROUND THE WORLD Revenue Growth and Diversification ~13 % CAGR Compan
Slide 5: Seasoned Leadership Team Driving Growth Strategy
SEASONED LEADERSHIP TEAM DRIVING GROWTH STRATEGY 5 DECADES OF EXPERIENCE LEADING ORTHOPEDIC, REGENERATIVE MEDICINE, AND MEDICAL DEVICE COMPANIES Mike Levitz EVP, CFO & Treasurer 2020 David Colleran EVP, General Counsel & Corporate Secretary 2020 James Chase SVP, International Sales & Marketing 2018
Slide 6: Experienced and Diversified Board of Directors
EXPERIENCED AND DIVERSIFIED BOARD OF DIRECTORS 6 Jeffery Thompson Chair of the Board Operating Partner HealthEdge Investment Partners, LLC Joined: 2011 Susan Vogt Chair of Nom/Gov Comm . Former President & CEO Aushon Biosystems, Inc. Joined: 2018 Jack Henneman Chair of Compensation Comm. Former Corp
Slide 7: Multi-Year Strategy for Value Creation
MULTI - YEAR STRATEGY FOR VALUE CREATION 7 KEY FOCUS AREAS • Assembled talented/experienced leadership • Integrated Arthrosurface and Parcus to accelerate growth • Transformed commercial execution • Increased and aligned R&D, quality, and operations to scale • Drove revenue diversification 2020 – 20
Slide 8: Our Focus on ESG
8 OUR FOCUS ON ESG - ENVIRONMENTAL, SOCIAL AND GOVERNANCE OUR FOCUS ON ESG INCLUDES SENIOR LEADERSHIP TEAM OWNERSHIP AND CONTINUOUS BOARD OF DIRECTOR OVERSIGHT • In 2021, Anika embarked on a journey to develop a foundational ESG (Environmental, Social, Governance) framework aligned with our corporat
Slide 9: Proposal #2 – Amendment of 2017 Omnibus Incentive Plan
PROPOSAL #2 – AMENDMENT OF 2017 OMNIBUS INCENTIVE PLAN 9 • The Board recommends that you vote FOR the approval of the Amendment to the 2017 Omnibus Incentive Plan • The strategic transformation of Anika requires experienced and motivated employees with expanded skills, capabilities and experience •
Slide 10: Proposal #4 – Advisory Say-on-Pay
PROPOSAL #4 – ADVISORY SAY - ON - PAY 10 • The Board recommends that you vote FOR the advisory “Say - on - Pay” vote x Executive compensation program designed to link pay with performance x Average ~85 % Say - on - Pay approval last 4 years x Balanced approach Pay - For - Performance Compensation El
Slide 11: Summary
11 Anika is laser focused on becoming the leader in joint preservation – one of the highest opportunity spaces in orthopedics 01 2022 is a foundational year of execution on our product pipeline and commercial strategy to deliver targeted value to the ASC in early intervention orthopedics 02 03 04 SU
Slide 12: Safe Harbor Statements
SAFE HARBOR STATEMENTS Cautionary Note on Forward - looking Statements The statements made in, and during the course of, this presentation that are not statements of historical fact, including tho se related to the Company’s commercial capabilities, initiatives and production, its product pipeline a